AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Completed · Phase 1, Phase 2 · NCT02556736
Conditions: Advanced Retinitis Pigmentosa
At a glance
- Research payments reported, 2025
- $24,644
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 14
About the trial
- Sponsor
- AbbVie
- Tested
- AGN-151597 (drug)
- Dates
- Started 2015-12-14; completion 2024-10-21
- Results posted
- Yes
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
From ClinicalTrials.gov, last updated 2026-01-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $24,644 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.